A human life-stage physiologically based pharmacokinetic and pharmacodynamic model for chlorpyrifos: development and validation.

Sensitivity to some chemicals in animals and humans are known to vary with age. Age-related changes in sensitivity to chlorpyrifos have been reported in animal models. A life-stage physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model was developed to predict disposition of chlorpyrifos and its metabolites, chlorpyrifos-oxon (the ultimate toxicant) and 3,5,6-trichloro-2-pyridinol (TCPy), as well as B-esterase inhibition by chlorpyrifos-oxon in humans. In this model, previously measured age-dependent metabolism of chlorpyrifos and chlorpyrifos-oxon were integrated into age-related descriptions of human anatomy and physiology. The life-stage PBPK/PD model was calibrated and tested against controlled adult human exposure studies. Simulations suggest age-dependent pharmacokinetics and response may exist. At oral doses ⩾0.6mg/kg of chlorpyrifos (100- to 1000-fold higher than environmental exposure levels), 6months old children are predicted to have higher levels of chlorpyrifos-oxon in blood and higher levels of red blood cell cholinesterase inhibition compared to adults from equivalent doses. At lower doses more relevant to environmental exposures, simulations predict that adults will have slightly higher levels of chlorpyrifos-oxon in blood and greater cholinesterase inhibition. This model provides a computational framework for age-comparative simulations that can be utilized to predict chlorpyrifos disposition and biological response over various postnatal life stages.

[1]  V. Drossou,et al.  Serum concentrations of 10 acute-phase proteins in healthy term and preterm infants from birth to age 6 months. , 1995, Clinical chemistry.

[2]  S. Haddad,et al.  In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. , 2012, Journal of pharmaceutical sciences.

[3]  E. Duysen,et al.  Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. , 2005, Biochemical pharmacology.

[4]  T. Poet,et al.  In vitro rat hepatic and intestinal metabolism of the organophosphate pesticides chlorpyrifos and diazinon. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  C. Furlong,et al.  Determination of paraoxonase (PON1) status requires more than genotyping. , 1999, Pharmacogenetics.

[6]  C. Willhite,et al.  Derivation of a Bisphenol a Oral Reference Dose (RfD) and Drinking-Water Equivalent Concentration , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.

[7]  J. Richardson,et al.  Effects of Repeated Oral Postnatal Exposure to Chlorpyrifos on Open-field Behavior in Juvenile Rats Table 1 Daily Deaths Occurring during Repeated Oral Exposure to Three Dosages of Chlorpyrifos from Pnd 1 through 21 , 2022 .

[8]  S. Brimijoin,et al.  Comparison of the in vitro sensitivity of rat acetylcholinesterase to chlorpyrifos-oxon: what do tissue IC50 values represent? , 1998, Toxicology and applied pharmacology.

[9]  P. McNamara,et al.  Evaluation of the Assumptions of an Ontogeny Model of Rat Hepatic Cytochrome P450 Activity , 2007, Drug Metabolism and Disposition.

[10]  John C Lipscomb,et al.  In vitro measurements of metabolism for application in pharmacokinetic modeling. , 2008, Pharmacology & therapeutics.

[11]  Corie A Ellison,et al.  Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion. , 2011, Toxicology.

[12]  F. Sidell,et al.  Influence of age, sex, and oral contraceptives on human blood cholinesterase activity. , 1975, Clinical chemistry.

[13]  Yuehe Lin,et al.  Pharmacokinetics of the chlorpyrifos metabolite 3,5,6-trichloro-2-pyridinol (TCPy) in rat saliva. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  C. Pope,et al.  Comparative cholinergic neurotoxicity of oral chlorpyrifos exposures in preweanling and adult rats. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  Dana B Barr,et al.  Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat. , 2009, Toxicology.

[16]  Jane Alcorn,et al.  Pharmacokinetics in the newborn. , 2003, Advanced drug delivery reviews.

[17]  J. Bakke,et al.  Rat urinary metabolites from O,O-diethyl-O-(3,5,6-trichloro-2-pyridyl) phosphorothioate. , 1976, Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes.

[18]  G. Tucker,et al.  Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. , 2003, British journal of clinical pharmacology.

[19]  M. Bartels,et al.  In Vitro Age-Dependent Enzymatic Metabolism of Chlorpyrifos and Chlorpyrifos-Oxon in Human Hepatic Microsomes and Chlorpyrifos-Oxon in Plasma , 2011, Drug Metabolism and Disposition.

[20]  M Sue Marty,et al.  The effect of plasma lipids on the pharmacokinetics of chlorpyrifos and the impact on interpretation of blood biomonitoring data. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  Yu-Jui Yvonne Wan,et al.  Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. , 2009, Biochemical pharmacology.

[22]  J. Cocker,et al.  Biotransformation of chlorpyrifos and diazinon by human liver microsomes and recombinant human cytochrome P450s (CYP) , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  Charles Timchalk,et al.  An age-dependent physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus insecticide chlorpyrifos in the preweanling rat. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  R. Carr,et al.  Changes in rat brain cholinesterase activity and muscarinic receptor density during and after repeated oral exposure to chlorpyrifos in early postnatal development. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[25]  D. M. Maxwell,et al.  The effects of blood flow and detoxification on in vivo cholinesterase inhibition by soman in rats. , 1987, Toxicology and applied pharmacology.

[26]  C Timchalk,et al.  Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat. , 2008, Neurotoxicology.

[27]  Melvin E. Andersen,et al.  Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropyfluorophosphate , 1990 .

[28]  Harvey J Clewell,et al.  Bayesian Estimation of Pharmacokinetic and Pharmacodynamic Parameters in a Mode‐of‐Action‐Based Cancer Risk Assessment for Chloroform , 2007, Risk analysis : an official publication of the Society for Risk Analysis.

[29]  Children.  Pesticides in the Diets of Infants and Children , 1993 .

[30]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[31]  Harvey J Clewell,et al.  Perchlorate and Radioiodide Kinetics Across Life Stages in the Human: Using PBPK Models to Predict Dosimetry and Thyroid Inhibition and Sensitive Subpopulations Based on Developmental Stage , 2007, Journal of toxicology and environmental health. Part A.

[32]  M. Beck,et al.  Cholinesterase inhibition and toxicokinetics in immature and adult rats after acute or repeated exposures to chlorpyrifos or chlorpyrifos-oxon. , 2012, Regulatory toxicology and pharmacology : RTP.

[33]  K Krishnan,et al.  An algorithm for predicting tissue: blood partition coefficients of organic chemicals from n-octanol: water partition coefficient data. , 1995, Journal of toxicology and environmental health.

[34]  C. Pope,et al.  Carboxylesterase and A-esterase activities during maturation and aging: relationship to the toxicity of chlorpyrifos and parathion in rats. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[35]  John F. Young,et al.  Postnatal Growth Considerations for PBPK Modeling , 2007, Journal of toxicology and environmental health. Part A.

[36]  T. Poet,et al.  Regional Brain Dosimetry for the Organophosphorus Insecticide Chlorpyrifos in the Preweanling Rat , 2012 .

[37]  Paul S Price,et al.  Application of a source-to-outcome model for the assessment of health impacts from dietary exposures to insecticide residues. , 2011, Regulatory toxicology and pharmacology : RTP.

[38]  S. Haddad,et al.  Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. , 2011, Journal of pharmaceutical sciences.

[39]  C. Pope,et al.  Comparison of in vivo cholinesterase inhibition in neonatal and adult rats by three organophosphorothioate insecticides. , 1991, Toxicology.

[40]  R. Reiss,et al.  Acetylcholinesterase inhibition dose-response modeling for chlorpyrifos and chlorpyrifos-oxon. , 2012, Regulatory toxicology and pharmacology : RTP.

[41]  C. Lafortuna,et al.  Gender variations of body composition, muscle strength and power output in morbid obesity , 2005, International Journal of Obesity.

[42]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[43]  Yan Jiang,et al.  Age- and Sex-Related Expression and Activity of Carboxylesterase 1 and 2 in Mouse and Human Liver , 2009, Drug Metabolism and Disposition.

[44]  L G Sultatos,et al.  Mammalian toxicology of organophosphorus pesticides. , 1994, Journal of toxicology and environmental health.

[45]  G. Jarvik,et al.  Paraoxonase 1 (PON1) status and substrate hydrolysis. , 2009, Toxicology and applied pharmacology.

[46]  Paul S Price,et al.  Development of a source-to-outcome model for dietary exposures to insecticide residues: an example using chlorpyrifos. , 2011, Regulatory toxicology and pharmacology : RTP.

[47]  Hongshik Ahn,et al.  Human Organ/Tissue Growth Algorithms that Include Obese Individuals and Black/White Population Organ Weight Similarities from Autopsy Data , 2009, Journal of toxicology and environmental health. Part A.

[48]  R. A. Neal,et al.  Studies of the metabolism of parathion with an apparently homogeneous preparation of rabbit liver cytochrome P-450. , 1976, Drug metabolism and disposition: the biological fate of chemicals.

[49]  O. Svensmark,et al.  CARBOXYLESTERASES WITH DIFFERENT SUBSTRATE SPECIFICITY IN HUMAN BRAIN EXTRACTS , 1976, Journal of neurochemistry.

[50]  J. Lipscomb,et al.  Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.

[51]  Dale Hattis,et al.  Physiologically Based Pharmacokinetic (PBPK) Modeling of Caffeine and Theophylline in Neonates and Adults: Implications for Assessing Children's Risks from Environmental Agents , 2004, Journal of toxicology and environmental health. Part A.

[52]  Walter Schmitt,et al.  General approach for the calculation of tissue to plasma partition coefficients. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[53]  T. Slotkin,et al.  Developmental neurotoxicity of chlorpyrifos: cellular mechanisms. , 1995, Toxicology and Applied Pharmacology.

[54]  J. Olson,et al.  Pharmacokinetics and pharmacodynamics of chlorpyrifos in adult male Long-Evans rats following repeated subcutaneous exposure to chlorpyrifos. , 2011, Toxicology.

[55]  T. Poet,et al.  Age-dependent pharmacokinetic and pharmacodynamic response in preweanling rats following oral exposure to the organophosphorus insecticide chlorpyrifos. , 2006, Toxicology.

[56]  D. Barr,et al.  Comparative pharmacokinetics of chlorpyrifos versus its major metabolites following oral administration in the rat. , 2010, Toxicology.

[57]  J. Bruckner.  Differences in sensitivity of children and adults to chemical toxicity: the NAS panel report. , 2000, Regulatory toxicology and pharmacology : RTP.

[58]  C Timchalk,et al.  A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[59]  Dana B Barr,et al.  Comparative pharmacokinetics of the organophosphorus insecticide chlorpyrifos and its major metabolites diethylphosphate, diethylthiophosphate and 3,5,6-trichloro-2-pyridinol in the rat. , 2007, Toxicology.

[60]  L. Sultatos,et al.  Comparison of chlorpyrifos-oxon and paraoxon acetylcholinesterase inhibition dynamics: potential role of a peripheral binding site. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[61]  Chensheng Lu,et al.  The Implications of Using a Physiologically Based Pharmacokinetic (PBPK) Model for Pesticide Risk Assessment , 2009, Environmental health perspectives.

[62]  C. Pope,et al.  Comparative neurochemical effects of repeated methyl parathion or chlorpyrifos exposures in neonatal and adult rats. , 1999, Toxicology and applied pharmacology.

[63]  C. Pope,et al.  Comparative carboxylesterase activities in infant and adult liver and their in vitro sensitivity to chlorpyrifos oxon. , 2005, Regulatory toxicology and pharmacology : RTP.

[64]  S. Barone,et al.  Tissue Carboxylesterases and Chlorpyrifos Toxicity in the Developing Rat , 2002 .

[65]  T. Poet,et al.  Age-related brain cholinesterase inhibition kinetics following in vitro incubation with chlorpyrifos-oxon and diazinon-oxon. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[66]  V. Moser,et al.  Gestational exposure to chlorpyrifos: dose response profiles for cholinesterase and carboxylesterase activity. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[67]  A. Motulsky,et al.  Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. , 1989, Analytical biochemistry.

[68]  R. Ross,et al.  Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. , 2000, Journal of applied physiology.

[69]  Katherine M Flegal,et al.  Mean body weight, height, and body mass index, United States 1960-2002. , 2004, Advance data.

[70]  C. Coyne,et al.  Purification of two rat hepatic proteins with A-esterase activity toward chlorpyrifos-oxon and paraoxon. , 1998, The Journal of pharmacology and experimental therapeutics.

[71]  P. McCall,et al.  Estimation of chemical mobility in soil from liquid chromatographic retention times , 1980, Bulletin of environmental contamination and toxicology.

[72]  C. Vidair.  Age dependence of organophosphate and carbamate neurotoxicity in the postnatal rat: extrapolation to the human. , 2004, Toxicology and applied pharmacology.

[73]  V. Moser,et al.  Tissue-specific effects of chlorpyrifos on carboxylesterase and cholinesterase activity in adult rats: an in vitro and in vivo comparison. , 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[74]  J. Albers,et al.  Paraoxonase status and plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers , 2010, Journal of Exposure Science and Environmental Epidemiology.

[75]  D. Rick,et al.  Chlorpyrifos: pharmacokinetics in human volunteers. , 1984, Toxicology and applied pharmacology.

[76]  M. Hooper,et al.  Rat brain acetylcholinesterase activity: developmental profile and maturational sensitivity to carbamate and organophosphorus inhibitors. , 1998, Toxicology.

[77]  J. Chambers,et al.  Age-related differences in parathion and chlorpyrifos toxicity in male rats: target and nontarget esterase sensitivity and cytochrome P450-mediated metabolism. , 1997, Toxicology and applied pharmacology.